The Ministry of Health of Uzbekistan has approved a list of diseases and medicines included in the reimbursement program. The document defines which drugs patients will be able to receive under reimbursement when treating socially significant diseases.
The document, signed by Minister Asilbek Khudayarov on April 23, 2026, was agreed with the State Health Insurance Fund and will come into force on January 1, 2027.
The list covers the main areas of chronic therapy — from cardiovascular diseases and diabetes to mental disorders and oncology. It includes both basic first-line drugs and certain modern classes of medicines.
Below is the full list of medicines included in the reimbursement program (the original document with the list in Uzbek is attached below).
LIST of diseases and medicines included in the reimbursement program
1. Oncology
| No. | Medicine | Dosage form |
|---|---|---|
| 1 | Tamoxifen | Tablets (10 mg; 20 mg) |
| 2 | Morphine hydrochloride | Solution for injection (1% 1 ml) |
| 3 | Omnopon | Solution for injection (1% 1 ml; 2% 1 ml) |
| 4 | Trimeperidine | Solution for injection (1% 1 ml; 2% 1 ml) |
| 5 | Tramadol | Solution for injection (5% 2 ml); capsules (50 mg) |
| 6 | Nalbuphine | Solution for injection (10 mg/1 ml) |
2. Mental disorders
| No. | Medicine | Dosage form |
|---|---|---|
| 7 | Lamotrigine | Tablets |
| 8 | Carbamazepine | Tablets |
| 9 | Benzobarbital | Tablets |
| 10 | Valproic acid | Tablets, capsules, syrup, drops, pediatric syrup, solution for injection |
| 11 | Clonazepam | Tablets (2 mg) |
| 12 | Aripiprazole | Tablets |
| 13 | Haloperidol | Tablets; solution for injection |
| 14 | Quetiapine | Tablets |
| 15 | Clozapine | Tablets |
| 16 | Olanzapine | Tablets |
| 17 | Fluphenazine decanoate | Solution for injection |
| 18 | Chlorpromazine | Tablets; solution for injection |
| 19 | Risperidone | Tablets |
| 20 | Thioridazine | Tablets |
| 21 | Trifluoperazine | Tablets; solution for injection |
| 22 | Amitriptyline | Tablets; solution for injection |
| 23 | Venlafaxine | Tablets (37.5 mg); capsules |
| 24 | Paroxetine | Tablets (20 mg) |
| 25 | Sertraline | Tablets (50 mg) |
| 26 | Trazodone | Tablets (150 mg) |
| 27 | Mirtazapine | Tablets (30 mg) |
| 28 | Escitalopram | Tablets (10 mg) |
3. Gastrointestinal diseases
| No. | Medicine | Dosage form |
|---|---|---|
| 29 | Omeprazole | Tablets (20 mg; 40 mg) |
4. Chronic obstructive pulmonary disease (COPD)
| No. | Medicine | Dosage form |
|---|---|---|
| 30 | Salbutamol | Aerosol (100 mcg/dose, 7 g, 200 doses) |
| 31 | Ambroxol | Tablets (30 mg) |
5. Endocrine diseases
| No. | Medicine | Dosage form |
|---|---|---|
| 32 | Potassium iodide | Tablets (200 mcg) |
| 33 | Thiamazole | Tablets (5 mg) |
| 34 | Levothyroxine sodium | Tablets (100 mcg) |
| 35 | Short-acting insulin 100 IU/10 ml | Solution for injection |
| 36 | Short-acting insulin analogue 100 IU/3 ml | Solution for injection |
| 37 | Long-acting insulin 100 IU/10 ml | Solution for injection; cartridge and prefilled pen* |
| 38 | Long-acting insulin analogue 100 IU/3 ml | Solution for injection; cartridge and prefilled pen* |
| 39 | Mixed insulin 100 IU/10 ml | Solution for injection; cartridge and prefilled pen* |
| 40 | Gliclazide | Tablets (30 mg; 60 mg) |
| 41 | Metformin | Tablets (500 mg; 1000 mg) |
| 42 | Empagliflozin | Tablets (10 mg; 25 mg) |
| 43 | Desmopressin | Nasal drops (100 mcg/ml, 5 ml); nasal spray (10 mcg/ml dose, 5 ml) |
| 44 | Hydrocortisone | Eye ointment (0.5%; 1%; 2.5%); ointment (0.1%); eye suspension (0.1%) |
| 45 | Prednisolone | Tablets (5 mg) |
6. Cardiovascular diseases
| No. | Medicine | Dosage form |
|---|---|---|
| 46 | Verapamil | Tablets |
| 47 | Isosorbide mononitrate | Tablets (20 mg; 40 mg) |
| 48 | Isosorbide dinitrate | Spray; tablets |
| 49 | Acetylsalicylic acid | Tablets (75 mg; 150 mg) |
| 50 | Clopidogrel | Tablets (75 mg) |
| 51 | Bisoprolol | Tablets (2.5 mg; 5 mg; 10 mg) |
| 52 | Amlodipine | Tablets (2.5 mg; 5 mg; 10 mg) |
| 53 | Enalapril | Tablets (2.5 mg; 5 mg; 10 mg; 20 mg) |
| 54 | Atorvastatin | Tablets (10 mg; 20 mg; 40 mg; 80 mg) |
| 55 | Spironolactone | Tablets (25 mg) |
| 56 | Furosemide | Tablets (40 mg); solution for injection (1% 2 ml) |
7. Diseases of the blood system
| No. | Medicine | Dosage form |
|---|---|---|
| 57 | Heparin | Solution for injection (5000 IU; 25000 IU; 12500 IU — 1 ml; 2 ml; 5 ml; 10 ml*) |
| 58 | Warfarin | Tablets (2.5 mg) |
| 59 | Iron (Fe II) preparations | Tablets (100 mg); capsules (100 mg) |
| 60 | Iron (Fe III) preparations | Tablets (100 mg); capsules (100 mg) |
| 61 | Folic acid | Tablets (1 mg; 5 mg) |
8. Parasitic diseases
| No. | Medicine | Dosage form |
|---|---|---|
| 62 | Albendazole | Tablets; suspension |
9. Age-related changes in the female reproductive system
| No. | Medicine | Dosage form |
|---|---|---|
| 63 | Drospirenone + ethinyl estradiol | Tablets |
10. Chronic liver diseases
| No. | Medicine | Dosage form |
|---|---|---|
| 64 | Ursodeoxycholic acid | Capsules (250 mg) |
11. Degenerative diseases of the central nervous system
| No. | Medicine | Dosage form |
|---|---|---|
| 65 | Inosine pranobex ** | Tablets (500 mg) |
12. Chronic renal and hepatic failure
| No. | Medicine | Dosage form |
|---|---|---|
| 66 | Cyclosporine | Capsules (25 mg; 50 mg; 100 mg) |
| 67 | Tacrolimus | Capsules (0.5 mg; 1.0 mg; 5.0 mg) |
| 68 | Mycophenolate mofetil | Tablets (250 mg; 500 mg); capsules (250 mg; 500 mg) |
| 69 | Mycophenolic acid | Tablets (180 mg; 360 mg) |
Notes:
* Prescribed for children under 15 years of age with type 1 diabetes
** Prescribed for patients with subacute sclerosing panencephalitis (A81.1)
The procedure for providing medicines under the reimbursement program is determined by Resolution No. 619 of the Cabinet of Ministers of the Republic of Uzbekistan dated October 2, 2024.
Attention! The analysis below reflects our analytical conclusions based on the approved list. This is an interpretation of the document’s structure, not official clarification.
Overall structure of the list
The list is organized by clinical categories and includes medicines for the treatment of the most common chronic diseases. The largest share of the list is devoted to cardiovascular diseases, endocrine disorders, mental health conditions, and respiratory diseases.
Structurally, the document is primarily oriented toward outpatient treatment — most medicines are intended for long-term use and control of chronic conditions.
At the same time, the list contains almost no expensive innovative drugs and mainly consists of basic first-line therapies.
Cardiovascular diseases — the strongest part of the list
The cardiology section includes standard baseline therapies used to treat hypertension, coronary artery disease, and heart failure. The list contains key classes of antihypertensive drugs, antiplatelets, and statins.
This set corresponds to the standard model of primary prevention of heart attacks and strokes. The availability of these medicines is considered a key element in reducing mortality from cardiovascular diseases.
At the same time, modern next-generation anticoagulants are absent from the list. A more traditional treatment model is used, typical of many budget-constrained systems.
Diabetes and endocrine diseases
The endocrinology section includes medicines for diabetes and thyroid disorders, as well as different types of insulin. The list contains both classic drugs and one modern class of glucose-lowering therapy.
This structure ensures basic diabetes treatment, but newer drugs with proven effects on cardiovascular mortality are not included. This limits the possibilities for expanded cardiometabolic therapy.
At the same time, the presence of insulin and basic oral medications covers the main needs of outpatient diabetes treatment.
Psychiatry — broad but heterogeneous list
The section on mental health includes antidepressants, antipsychotics, and antiepileptic drugs. The list features both modern medicines and older molecules that are used more selectively in some countries.
This approach provides broad access to treatment but makes the list heterogeneous in terms of how up-to-date the medicines are.
Overall, the psychiatric section can be considered one of the most comprehensively represented in the document.
Oncology — basic therapy and pain management
The oncology section includes hormone therapy and pain relief medicines, including opioid analgesics. This means the system covers the basic needs of outpatient treatment and palliative care.
However, modern targeted therapies and immunotherapy are not included. Such drugs are typically part of more expensive insurance systems and usually require separate funding.
Thus, the oncology section is focused on basic treatment support rather than advanced anti-cancer therapy.
Respiratory diseases
This section includes medicines for symptomatic treatment of chronic respiratory diseases, with a primary focus on fast-acting drugs.
Baseline inhalation therapy, widely recommended internationally for long-term control of chronic lung diseases, is largely absent from the list. This indicates a simplified outpatient treatment model for such conditions.
Hematology and immunosuppressive therapy
The list includes medicines for anemia correction, anticoagulants, and immunosuppressive drugs used after organ transplantation. This set corresponds to a basic level of therapy and covers core clinical needs.
At the same time, modern next-generation anticoagulants are not included, which distinguishes this list from more comprehensive insurance formularies.
What the analysis of the list shows
The structure of the document indicates the formation of a basic drug reimbursement system focused on the most common chronic diseases. The main emphasis is on affordable generics and first-line therapies.
Cardiology, diabetes, and psychiatry are the most fully represented areas. These fields occupy a key place in the structure of chronic morbidity and mortality.
Less developed are sections related to innovative therapies — primarily oncology, modern anticoagulants, and advanced treatment regimens for chronic lung diseases.
Overall, the list establishes a baseline level of pharmaceutical coverage focused on widespread diseases and outpatient care.